BrightPath and Artisan Bio sign agreement to expedite cell therapies
03 May 2023
License out/inCell TherapyClinical Study
Preview
Source: Pharmaceutical Technology
BrightPath will receive rights to Artisan Bio’s STAR-CRISPR editing platform. Credit: Herney Gómez from Pixabay.
Preview
Source: Pharmaceutical Technology
BrightPath Biotherapeutics and Artisan Bio have signed a research and licensing agreement to expedite the former’s allogeneic next-generation invariant natural killer T (iNKT) cell therapies to clinic.
BrightPath will obtain non-exclusive rights to the STAR-CRISPR editing platform of Artisan Bio for accelerating the development of BrightPath’s iNKT cells.
BrightPath Biotherapeutics CEO Kenichi Nagai stated: “This collaboration with Artisan provides us with the potential to create highly engineered allogeneic iNKT cellular therapy programmes for a range of indications, including solid tumours.
“Artisan’s STAR-CRISPR system, and their leading editing efficiencies in iPSC cells, will enable our iNKT cell therapies to solve the persistence and efficacy problems faced by first-generation allogeneic CAR-T programmes.”
Artisan will receive an upfront payment and research milestone payments, along with licence fees and development milestones from BrightPath.
The company will also receive net sales milestones and royalties on future products.
Artisan Bio CEO Ryan Gill stated: “We are excited for the BrightPath collaboration and the development of highly engineered iPS cells for cell therapy.
“The BrightPath products will build upon our leading STAR-CRISPR platform, our highly optimised guides for allogeneic and proprietary target genes, and our rigorous off-target safety profiling.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free Whitepaper
Optimise your cell therapy process: a guide to cell thawing
Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.
This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
By Cytiva Thematic
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.